Oppenheimer analyst Matthew Biegler maintained a Buy rating on Fate Therapeutics (NASDAQ:FATE) on Sunday, setting a price target of $135, which is approximately 85.47% above the present share price of $72.79.
Biegler expects Fate Therapeutics to post earnings per share (EPS) of -$0.48 for the second quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Fate Therapeutics, with an average price target of $109.5.
The analysts price targets range from a high of $145 to a low of $80.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $11.14 million and a net profit of -$46.21 million. The company's market cap is $6.84 billion.
According to TipRanks.com, Oppenheimer analyst Matthew Biegler is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 29.4% and a 48.33% success rate.
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.